The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 4, 2006, Pages 637-653

  Baron, Frédéric ^a   Storb, Rainer ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

graft versus tumor effects; hematopoietic cell transplantation; immunotherapy; monoclonal antibody

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CALICHEAMICIN; CANCER VACCINE; CYCLOPHOSPHAMIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD33; MONOCLONAL ANTIBODY CD45; RITUXIMAB; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DESIGN; DRUG TARGETING; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HISTORY OF MEDICINE; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; LYMPHOCYTE TRANSFUSION; LYMPHOMA; MELANOMA; NATURAL KILLER CELL; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; WHOLE BODY RADIATION;

HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY;

EID: 33748855004     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.06.002     Document Type: Review

References (107)

1. Ehrlich P. Ueber den jetzigen stand der Karzinomforschung. Nederlands Tijdschrift voor Geneeskunde 5 (1909) 273-290
2. Schwartz R.S. Another look at immunologic surveillance (Review). The New England Journal of Medicine 293 4 (1975) 181-184
3. Burnet M. The Clonal Selection Theory of Acquired Immunity (1959), Cambridge University Press, London
4. Burnet F.M. The concept of immunological surveillance (Review). Progress in Experimental Tumor Research 13 (1970) 1-27
5. Thomas L. On immunosurveillance in human cancer. Yale Journal of Biology & Medicine 55 3-4 (1982) 329-333
6. Wilson D.B. Immunological surveillance. Science 169 949 (1970) 1006-1011
7. Stutman O. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. Journal of the National Cancer Institute 62 2 (1979) 353-358
8. Dunn G.P., Bruce A.T., Ikeda H., et al. Cancer immunoediting: from immunosurveillance to tumor escape (Review). Nature Immunology 3 11 (2002) 991-998
9. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting (Review). Immunity 21 2 (2004) 137-148
10. Kaplan D.H., Shankaran V., Dighe A.S., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America 95 13 (1998) 7556-7561
11. Smyth M.J., Thia K.Y., Street S.E., et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. The Journal of Experimental Medicine 192 5 (2000) 755-760
12. Shankaran V., Ikeda H., Bruce A.T., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 6832 (2001) 1107-1111
13. Birkeland S.A., Storm H.H., Lamm L.U., et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. International Journal of Cancer 60 2 (1995) 183-189
14. Engels E.A., and Goedert J.J. Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer: past, present, and future. Journal of the National Cancer Institute 97 6 (2005) 407-409
15. Thomas E.D., Lochte Jr. H.L., Lu W.C., et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. The New England Journal of Medicine 257 (1957) 491-496
16. Little M.-T., and Storb R. History of haematopoietic stem-cell transplantation. Nature Reviews Cancer 2 (2002) 231-238
17. Mathe G., Amiel J.L., Schwarzenberg L., et al. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Research 25 9 (1965) 1525-1531
18. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. The New England Journal of Medicine 300 (1979) 1068-1073
19. Weiden P.L., Sullivan K.M., Flournoy N., et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. The New England Journal of Medicine 304 (1981) 1529-1533
20. Morris E., Hart D., Gao L., et al. Generation of tumor-specific T-cell therapies. Blood Reviews 20 (2006) 61-69
21. Maloney D.G. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines (Review). Journal of Clinical Oncology 23 26 (2005) 6421-6428
22. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 10 (2002) 3554-3561
23. Sievers E.L., Larson R.A., Stadmauer E.A., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology 19 13 (2001) 3244-3254
24. Caligiuri M.A., Velardi A., Scheinberg D.A., et al. Immunotherapeutic approaches for hematologic malignancies (Review). Hematology (2004) 337-353
25. Pagel J.M., Matthews D.C., Appelbaum F.R., et al. The use of radioimmunoconjugates in stem cell transplantation (Mini-review). Bone Marrow Transplantation 29 (2002) 807-816
26. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107 (2006) 2184-2191
27. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Experimental Hematology 32 1 (2004) 28-35
28. Barnes D.W.H., and Loutit J.F. Treatment of murine leukaemia with x-rays and homologous bone marrow: II. British Journal of Haematology 3 (1957) 241-252
29. Bortin M.M., Rimm A.A., Rose W.C., et al. Graft-versus-leukemia. V. Absence of antileukemic effect using allogeneic H-2-identical immunocompetent cells. Transplantation 18 (1974) 280-283
30. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
31. Martin P.J., Hansen J.A., Buckner C.D., et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66 (1985) 664-672
32. Maraninchi D., Gluckman E., Blaise D., et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 2 (1987) 175-178
33. Sullivan K.M., Storb R., Buckner C.D., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. The New England Journal of Medicine 320 (1989) 828-834
34. Sullivan K.M., Weiden P.L., Storb R., et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73 (1989) 1720-1728
35. Kolb H.J., Mittermüller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 (1990) 2462-2465
36. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86 5 (1995) 2041-2050
37. Collins Jr. R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology 15 2 (1997) 433-444
38. Lokhorst H.M., Schattenberg A., Cornelissen J.J., et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Journal of Clinical Oncology 18 16 (2000) 3031-3037
39. Peggs K.S., Mackinnon S., and Linch D.C. The role of allogeneic transplantation in non-Hodgkin's lymphoma. British Journal of Haematology 128 2 (2005) 153-168
40. Kolb H.J., Schmidt C., Barrett A.J., et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103 3 (2004) 767-776
41. Storb R. Allogeneic hematopoietic stem cell transplantation - yesterday, today, and tomorrow. Experimental Hematology 31 (2003) 1-10
42. Baron F., and Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Seminars in Immunopathology 26 (2004) 71-94
43. Baron F., and Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders (Review). Molecular Therapy 13 1 (2006) 26-41
44. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 12 (1997) 4531-4536
45. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 3 (1998) 756-763
46. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 11 (2001) 3390-3400
47. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. The New England Journal of Medicine 343 11 (2000) 750-758
48. Morris E., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104 13 (2004) 3865-3871
49. Mohty M., de Lavallade H., Ladaique P., et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 19 6 (2005) 916-920
50. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Journal of Clinical Oncology 23 9 (2005) 1993-2003
51. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89 8 (1997) 3048-3054
52. Niederwieser D., Maris M., Shizuru J.A., et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101 4 (2003) 1620-1629
53. Maris M.B., Niederwieser D., Sandmaier B.M., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102 6 (2003) 2021-2030
54. Junghanss C., Marr K.A., Carter R.A., et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biology of Blood and Marrow Transplantation 8 (2002) 512-520
55. Weissinger F., Sandmaier B.M., Maloney D.G., et al. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 98 13 (2001) 3584-3588
56. Hogan W.J., Maris M., Storer B., et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 103 1 (2004) 78-84
57. Fukuda T., Hackman R.C., Guthrie K.A., et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 102 8 (2003) 2777-2785
58. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood 104 4 (2004) 961-968
59. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood 104 5 (2004) 1550-1558
60. Parikh C.R., Schrier R.W., Storer B., et al. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. American Journal of Kidney Diseases 45 3 (2005) 502-509
61. Chien J.W., Maris M.B., Sandmaier B.M., et al. Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 11 (2005) 288-296
62. Baron F., Baker J.E., Storb R., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 104 8 (2004) 2254-2262
63. + cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 19 (2005) 822-828
64. Sandmaier B.M., Maris M., Maloney D.G., et al. Low-dose total body irradiation (TBI) conditioning for hematopoietic cell transplants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies: a five-year experience. [Abstract]. Blood 102 (2003) (Part 1):(11)78a-9a, #264
65. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 2 (2003) 756-762
66. Feinstein L.C., Sandmaier B.M., Hegenbart U., et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. British Journal of Haematology 120 2 (2003) 281-288
67. Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 9 (2003) 3447-3454
68. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 12 (2004) 3535-3542
69. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. Journal of Clinical Oncology 23 16 (2005) 3819-3829
70. Kerbauy F.R., Storb R., Hegenbart U., et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 19 (2005) 990-997
71. Baron F., Maris M.B., Storer B.E., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biology of Blood and Marrow Transplantation 11 (2005) 272-279
72. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 (2006) 128-135
73. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia (AML) by low dose total body irradiation (TBI) based conditioning and hematopoietic cell transplantation (HCT) from related and unrelated donors. Journal of Clinical Oncology 24 (2006) 444-453
74. Herberman R.B., Djeu J., Kay H.D., et al. Natural killer cells: characteristics and regulation of activity. Immunological Reviews 44 (1979) 43-70
75. Livnat S., Seigneuret M., Storb R., et al. Analysis of cytotoxic effector cell function in patients with leukemia or aplastic anemia before and after marrow transplantation. Journal of Immunology 124 (1980) 481-490
76. Raff R.F., Loughran Jr. T.P., Deeg H.J., et al. Role of radiation-resistant large granular lymphocytes in the rejection of unrelated DLA-nonidentical marrow grafts in dogs. Transplantation Proceedings 19 (1987) 2718-2720
77. Raff R.F., Sandmaier B.M., Graham T., et al. 'Resistance' to DLA-nonidentical canine unrelated marrow grafts is unrestricted by the major histocompatibility complex. Experimental Hematology 22 (1994) 893-897
78. Fischer A., Le Deist F., Hacein-Bey-Abina S., et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy (Review). Immunological Reviews 203 (2005) 98-109
79. Moretta A., Bottino C., Vitale M., et al. Receptors for HLA class-I molecules in human natural killer cells (Review). Annual Review of Immunology 14 (1996) 619-648
80. Moretta L., Bottino C., Pende D., et al. Different checkpoints in human NK-cell activation (Review). Trends in Immunology 25 12 (2004) 670-676
81. Groh V., Wu J., Yee C., et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 6908 (2002) 734-738
82. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 5562 (2002) 2097-2100
83. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 3 (2003) 814-819
84. Davies S.M., Ruggieri L., DeFor T., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100 10 (2002) 3825-3827
85. Bornhauser M., Schwerdtfeger R., Martin H., et al. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 103 7 (2004) 2860-2861
86. Beelen D.W., Ottinger H.D., Ferencik S., et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 105 6 (2005) 2594-2600
87. Parham P., and McQueen K.L. Alloreactive killer cells: hindrance and help for haematopoietic transplants (Review). Nature Reviews Immunology 3 2 (2003) 108-122
88. Frohn C., Schlenke P., and Kirchner H. The repertoire of HLA-Cw-specific NK cell receptors CD158 a/b (EB6 and GL183) in individuals with different HLA phenotypes. Immunology 92 4 (1997) 567-570
89. Shilling H.G., Young N., Guethlein L.A., et al. Genetic control of human NK cell repertoire. Journal of Immunology 169 1 (2002) 239-247
90. Leung W., Iyengar R., Turner V., et al. Determinants of antileukemia effects of allogeneic NK cells. Journal of Immunology 172 1 (2004) 644-650
91. Bishara A., De Santis D., Witt C.C., et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63 3 (2004) 204-211
92. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes. Blood 105 12 (2005) 4878-4884
93. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine 6 9 (2000) 1018-1023
94. Bleakley M., and Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nature Reviews Cancer 4 5 (2004) 371-380
95. Walter E.A., Greenberg P.D., Gilbert M.J., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. The New England Journal of Medicine 333 (1995) 1038-1044
96. Heslop H.E., Smith C.A., Ng C., et al. Efficacy of adoptively transferred virus specific cytotoxic T lymphocytes for prophylaxis and treatment of EBV lymphoma. [Abstract]. Blood 88 (1996) (supplement 1): 681a, #2713
97. Rossig C., and Brenner M.K. Genetic modification of T lymphocytes for adoptive immunotherapy (Review). Molecular Therapy 10 1 (2004) 5-18
98. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nature Medicine 10 9 (2004) 909-915
99. Hsu F.J., Caspar C.B., Czerwinski D., et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89 9 (1997) 3129-3135
100. Miller R.A., Maloney D.G., Warnke R., et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. The New England Journal of Medicine 306 9 (1982) 517-522
101. Coscia M., Mariani S., Battaglio S., et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 18 1 (2004) 139-145
102. Timmerman J.M., Czerwinski D.K., Davis T.A., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99 5 (2002) 1517-1526
103. Köhler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 5517 (1975) 495-497
104. Linenberger M.L., Maloney D.G., and Bernstein I.D. Antibody-directed therapies for hematologic malignancies (Review). Trends in Molecular Medicine 8 2 (2002) 69-76
105. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 2 (1994) 435-445
106. Georges G.E., Maris M.B., Sandmaier B.M., et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation (HCT) for patients (pts) with poor risk, relapsed or refractory multiple myeloma. [Abstract]. Blood 104 (2004) (Part 1):(11)754a, #2756
107. Burroughs L.M., Maris M.B., Sandmaier B.M., et al. HLA-matched related (MRD) or unrelated donor (URD) non-myeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD). [Abstract]. Biology of Blood and Marrow Transplantation 10 (2004) (supplement 1):(2)73-4, #197